We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

139 hedge funds and large institutions have $472M invested in Ventyx Biosciences in 2025 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 30 increasing their positions, 41 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

246% more capital invested

Capital invested by funds: $136M → $472M (+$335M)

132% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 22

26% more funds holding

Funds holding: 110139 (+29)

11.69% more ownership

Funds ownership: 61.5%73.19% (+12%)

27% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 41

73% less call options, than puts

Call options by funds: $6.55M | Put options by funds: $23.8M

Holders
139
Holders Change
+29
Holders Change %
+26.36%
% of All Funds
1.69%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
51
Increased
30
Reduced
41
Closed
22
Calls
$6.55M
Puts
$23.8M
Net Calls
-$17.3M
Net Calls Change
-$17.7M
Name Holding Trade Value Shares
Change
Change in
Stake
AAA
1
Affinity Asset Advisors
New York
$58.6M +$19.1M +2,560,143 +65%
Morgan Stanley
2
Morgan Stanley
New York
$38.8M +$30.3M +4,049,194 +1,661%
Vanguard Group
3
Vanguard Group
Pennsylvania
$35.6M +$1.3M +173,569 +5%
BlackRock
4
BlackRock
New York
$28.4M +$14.6M +1,959,200 +166%
TCM
5
Tang Capital Management
California
$25.4M -$2.14M -286,000 -9%
BBA
6
Baker Bros. Advisors
New York
$21.2M +$9.91M +1,326,150 +130%
B
7
Braidwell
Connecticut
$17.3M +$14.4M +1,920,255 New
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$15M +$8.54M +1,142,786 +219%
MB
9
MPM BioImpact
Massachusetts
$14.8M +$12.2M +1,639,061 New
Citadel Advisors
10
Citadel Advisors
Florida
$14.1M -$2.36M -316,378 -17%
Connor, Clark & Lunn Investment Management (CC&L)
11
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$10.9M +$1.08M +144,174 +14%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$10.1M +$3.28M +438,297 +64%
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$9.54M -$16.1M -2,153,125 -67%
6CM
14
683 Capital Management
New York
$9.39M +$299K +40,000 +4%
Millennium Management
15
Millennium Management
New York
$8.94M -$4.95M -661,877 -40%
IC
16
Ikarian Capital
Texas
$8.66M -$2.62M -350,900 -27%
Jane Street
17
Jane Street
New York
$8.5M +$4.15M +555,963 +144%
Goldman Sachs
18
Goldman Sachs
New York
$7.56M +$3.22M +430,691 +106%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$6.98M +$521K +69,712 +10%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$6.7M +$2.4M +321,203 +76%
Balyasny Asset Management
21
Balyasny Asset Management
Illinois
$6.64M +$5.5M +735,711 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$6.53M -$47.6K -6,365 -0.9%
AGP
23
Artia Global Partners
Florida
$6.28M +$5.2M +695,982 New
Tudor Investment Corp
24
Tudor Investment Corp
Connecticut
$5.27M +$4.36M +583,611 New
State Street
25
State Street
Massachusetts
$4.96M +$1.95M +261,002 +91%

VTYX Hedge Fund Activity: Q4 2025 in Review

139 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q4 2025, worth a combined $472M — up 246% from $136M a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new VTYX positions and 22 closed out — a net gain of 29 holders — while 30 added to existing stakes and 41 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $30.3M. The largest seller was Point72 Asset Management, cutting an estimated $16.1M.

  • 139 institutional investors held Ventyx Biosciences (VTYX) as of Q4 2025, up from 110 in Q3 2025.
  • Funds reported $472M of Ventyx Biosciences stock for Q4 2025, up 246% quarter-over-quarter.
  • 51 funds opened new Ventyx Biosciences positions in Q4 2025 and 22 closed out, a net change of +29 holders.
  • The largest Ventyx Biosciences buyer in Q4 2025 was Morgan Stanley, an estimated $30.3M added.
  • The largest Ventyx Biosciences seller in Q4 2025 was Point72 Asset Management, an estimated $16.1M sold.

Based on aggregated 13F filings for Q4 2025.